Day One Biopharmaceuticals Inc

NASDAQ DAWN

Data sourced from iex and EODHD
Download Data

Day One Biopharmaceuticals Inc Earnings Per Share (EPS), Diluted 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 47.13%

Day One Biopharmaceuticals Inc Earnings Per Share (EPS), Diluted 3 year CAGR is 47.13% for the Trailing 12 Months (TTM) ending March 31, 2024, a -84.28% change year over year. Earnings Per Share (EPS), Diluted, is the portion of a company's profit allocated to each outstanding share of common stock, assuming the conversion of all potentially dilutive securities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Day One Biopharmaceuticals Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -2.34, a -125.59% change year over year.
  • Day One Biopharmaceuticals Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -1.04, a -187.00% change year over year.
  • Day One Biopharmaceuticals Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -0.36, a -887.61% change year over year.
  • Day One Biopharmaceuticals Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -0.04.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email